Safety and Immunogenicity of CRV-101 Vaccine for the Prevention of Herpes Zoster in Adults Aged 50 Years and Older (NCT05304351)

🧪 Interventions in This Study

• Amezosvatein Antigen High Dose Arm A (BIOLOGICAL)
• Amezosvatein Antigen Low Dose Arm B (BIOLOGICAL)
• Shingrix (BIOLOGICAL)
• Amezosvatein Adjuvant Dose Arm D (BIOLOGICAL)
• Amezosvatein Adjuvant Dose Arm F (BIOLOGICAL)
• Amezosvatein Adjuvant Dose Arm H (BIOLOGICAL)
• Amezosvatein Adjuvant Dose Arm J (BIOLOGICAL)
• Amezosvatein Adjuvant Dose Arm L (BIOLOGICAL)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (14 Sites)

• Curevo Investigational Site — Tempe, Arizona
• Curevo Investigational Site — Coral Gables, Florida
• Curevo Investigational Site — Tampa, Florida
• Curevo Investigational Site — Oak Brook, Illinois
• Curevo Investigational Site — Lenexa, Kansas
• Curevo Investigational Site — Newton, Kansas
• Curevo Investigational Site — Lexington, Kentucky
• Curevo Investigational Site — Las Vegas, Nevada
• Curevo Investigational Site — Edmond, Oklahoma
• Curevo Investigational Site — Knoxville, Tennessee
• Curevo Investigational Site — Austin, Texas
• Curevo Investigational Site — Dallas, Texas
• Curevo Investigational Site — Euless, Texas
• Curevo Investigational Site — Salt Lake City, Utah

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Herpes Zoster

• Safety of Herpes Zoster Subunit (HZ/su) Vaccine During Pregnancy in Adult Women With Immunocompromised Conditions — Canton, Massachusetts
• A Study on the Long-term Efficacy, Safety and Persistence of Immune Response of a Vaccine Against Herpes Zoster in Older Adults — Phoenix, Arizona
• Safety and Immunogenicity of Recombinant Varicella Zoster Virus Vaccine in People With HIV Who Have a CD4 Count Less Than 300 or Greater Than or Equal to 300 and a Healthy Control Population — Bethesda, Maryland

Explore by condition: All Herpes Zoster clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Review the official NIH record below to find the coordinating site.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.